Reik R A, Burch J W, Vassallo R R, Trainor L
ViaPath Enterprises, Inc., Loxahatchee, FL 33470, USA.
Vox Sang. 2006 May;90(4):255-64. doi: 10.1111/j.1423-0410.2006.00758.x.
On occasion, there arise questions or situations involving blood-donor eligibility determination, which are not adequately addressed by the existing regulations and standards. In such instances, even the most experienced blood collector may be uncertain regarding the best course of action and unable to find adequate guidance in the standard blood banking references, regulations and literature. In order to examine this area in greater depth, the American Association of Blood Banks (AABB) sponsored a short topic session on 'Unique Donor Suitability Issues' at their 2004 annual meeting. The invited speakers were four seasoned physician medical directors, with a combined experience of over 40 years in blood collection at both regional and national levels. They were tasked with identifying and researching problematic areas in donor-suitability determination, and suggesting an overall approach to dealing with such issues. They determined that three of the most problematic areas of eligibility evaluation included donors with: (1) disabilities, (2) disorders of haemostasis, and (3) trans-sexual, homosexual and other unusual gender-related issues. Each of these topics was presented in a 10-min lecture, followed by an open format consisting of audience participation and panel discussion by the speakers. The session was additionally enhanced by a representative of the United States Food and Drug Administration (FDA) who participated as a member of the audience. This review presents the contents of the short topic session in an expanded form.
有时会出现一些涉及献血者资格判定的问题或情况，现有法规和标准并未对其进行充分阐述。在这种情况下，即使是最有经验的采血人员也可能不确定最佳行动方案，并且无法在标准的血库参考资料、法规和文献中找到充分的指导。为了更深入地研究这一领域，美国血库协会（AABB）在其2004年年会上主办了一场关于“独特的献血者适宜性问题”的简短主题会议。受邀发言者是四位经验丰富的内科医学主任，他们在地区和国家层面的采血工作中积累了超过40年的综合经验。他们的任务是识别和研究献血者适宜性判定中的问题领域，并提出处理此类问题的总体方法。他们确定，资格评估中三个最具问题的领域包括具有以下情况的献血者：（1）残疾，（2）止血障碍，以及（3）变性者、同性恋者和其他与性别相关的特殊问题。每个主题都进行了10分钟的讲座，随后是开放式讨论，包括听众参与和发言者的小组讨论。美国食品药品监督管理局（FDA）的一名代表作为听众参与了会议，这进一步丰富了会议内容。本综述以扩展形式呈现了简短主题会议的内容。
